MedWatch Article

 

 

 

 

 

 

 

The Danish magazine MedWatch has released an article about PentaBase as top story in their newsletter today (12/16/2019). The article is about PentaBase and our newly received Innobooster-funding from Innovationsfonden.

The last two years, MicroSight® MSI test has been of highest priority for PentaBase and the product is soon ready to be released to the market. MicroSight® MSI is the first method to give an objective answer on a patients MSI status from known biomarkers – all this in less than two hours. It is therefore a great honor to have received Innobooster-funding from Innovationsfunden. The Innobooster-funding will be used to make the product fully ready for the market and for further optimization of MicroSight® MSI, which includes expansion of the test for use in more cancers.

To read the article please use the link below.

https://medwatch.dk/secure/laboratorie___diagnostik/article11807022.ece

 

Jens Lyager has joined PentaBase as Chief Commercial Officer

As part of PentaBase´s efforts to consolidate the market acceptance of our real-time PCR-based assays with game-changing sensitivity, Jens Lyager has joined PentaBase as Chief Commercial Officer.
Jens Lyager brings substantial experience in commercial development from top ranking life science companies launching innovative technologies. “I am impressed with the PentaBase product portfolio and especially with the ability it brings to truly monitor the real time effect of cancer treatments. It brings valuable information needed to optimize and personalize health care for thousands of cancer patients world wide”, says Jens Lyager.

Meet us at Vårmöte 2019 Patologi, 15-17 May in…

PentaBase is participating in the Vårmöte 2019 Patologi in Linköping, Sweden. Please drop by our booth and learn more about our innovative PCR-based assays for molecular pathology. We will be showcasing our SensiScreen® and PlentiPlex™ IVD products as well as our new MicroSIght assay for detection of Microsatellite Instability by real-time PCR.

PentaBase takes another leap forward with the appointment of…

CEO Ulf Bech Christensen (middle) welcomes Simon Rye Clausen (left), Henrik Schmidt (right) to the PentaBase board.

 

As part of PentaBase´s efforts to consolidate the market acceptance of our real-time PCR-based assays with game-changing sensitivity, the company has strengthened the organization in general and the Board of Directors in particular to focus the strategy of the company moving forward. Thus, the PentaBase Board has gained important experience by appointing two new Directors:

Simon Rye Clausen, MD
Simon has over 30 years of experience from the pharma industry. He has worked in Roche, Pfizer, Indivior and Eli Lilly pharmaceuticals, as well as being general manager of Life Technologies in Denmark. Simon was the original founder and CEO of the biotech company Genesto A/S and has serial experience in life-science start-up bridging into market opportunities of improved sales and marketing capabilities.
“I am excited by PentaBase and its technologies and solutions, which help patients with a disease specific genetic profile to get better treatment. Their products seem game-changing and set their own higher standard – while at the same time simply can be used on most PCR-platforms”, says Simon Rye Clausen, Chairman of the Board of Directors at PentaBase.

Henrik Schmidt, MBA
Henrik has worked 25 years in international business of medical diagnostics and devices, predominantly in Roche Diabetes Care and Medtrum Tech. Furthermore, Henrik has been involved in successful entrepreneurial businesses throughout his career.
“I see plenty of opportunities to engage with collaborators around the Globe with the easy-to-apply PentaBase assays to ensure optimized treatment to the individual patients for the benefit of the patient, relatives and payors hereby using scarce healthcare resources intelligently”, says Henrik Schmidt

The two Directors are developing the PentaBase strategy with the management team and its advisors, and wish to further strengthen the platform of knowledge and experience with quality diagnostic assays integrated at full into the clinical reality of patients’ lives.

PentaBase is now ISO 9001:2015 and ISO 13485:2016 certified

PentaBase is proud to announce that we are now ISO 9001:2015 and ISO 13485:2016 certified.

PentaBase is manufacturing and marketing oligonucleotides and in vitro diagnostic products based on standard and own proprietary chemistries, for researchers, IVD companies and healthcare customers worldwide. As part of our continuing efforts to provide high quality products and services to our customers, PentaBase has developed and implemented a quality management system that meets the requirements of both ISO 9001:2015 and ISO 13485:2016 quality standards. While ISO 9001:2015 is focused on continuous improvement of processes to meet the needs of customers and other stakeholders, ISO 13485:2016 is specifically focsused on the requirements for a comprehensive quality management system for the design and manufacture of medical devices.

PentaBase ISO 9001 Certificate

PentaBase ISO 13485 Certificate

PentaBase and Resnova sign a strategic agreement for SensiScreen®…

PentaBase and Resnova are pleased to announce their recent partnership agreement for the new exclusive distribution in Italy of PentaBase’ SensiScreen® test kit range conceived for the somatic mutation detection in cancer patients.

PentaBase ApS is a privately-owned Company founded in 2006, based in Odense (Denmark), rooted in the Intercalating Nucleic Acid invention, INA®.
Currently, INA® technology has been optimized, and includes proprietary monomers called “pentabases”. Such modified oligonucleotides show innovative and unique features that make them optimal for alternative approaches for genetic analysis. This platform has been used for the development of diagnostic kits, mainly based on the real-time PCR technique.

Resnova S.r.l. is an Italian, Rome-based, Distribution Company that, for over 21 Years of active presence in the Italian Marketplace, has acquired a leading position, on the entire Italian Territory. Its wide range portfolio of innovative solutions for in the Molecular Cytogenetic, Molecular and Cellular Biology fields for Advanced Diagnostics and Research/Biotechnologies Laboratories is obtained as result of alliances and exclusive distributor partnerships established with selected and innovating Biotech Companies worldwide.

“We found that Resnova, thanks to its long–lasting experience and specialization in the Molecular Advanced Diagnostics field, represents the ideal partner for our growth in Italy”, said Ulf Bech Christensen, Founder and CEO at PentaBase. “Resnova’s Team, thanks to the strong experience and active presence, will help PentaBase to offer Italian scientists and researchers, operating in Diagnostics Labs, a capillary and specialized technical support for the enhancement of innovative PentaBase Products diffusion in the Italian marketplace”

“We are very excited about the perspective to further expand our range of activities into the oncology field by partnering with an innovative Company focused on the development and commercialization of a new generation of molecular diagnostics tools, that combine ultra-high sensitivity with multiplexing capabilities, in full continuity with our existing successful distribution experiences and range of solutions”, said Sergio Centanaro, Managing Director at Resnova.

For further information or details please contact one of PentaBase or Resnova’s Representatives to the below listed addresses:

• Ulf Bech Christensen
  ubc@pentabase.com
  https://www.pentabase.com

• Sergio Centanaro
  scent@resnovaweb.it
  http://www.resnovaweb.com